drugset
drugset / Trial / NCT00032292

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

NCT00032292 ↗

Phase 1/2 Completed 34 enrolled Facet Biotech
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease (GVHD). Patients will be eligible for enrollment within 24 hours of beginning standard steroid treatment. The research is being conducted at up to 10 clinical research sites in the US.

Timeline

Start
2002-03
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Visilizumab Monoclonal antibody — —

Indications

acute graft versus host disease